The epidermal growth factor receptor inhibitors market is driven by the increasing prevalence of cancers, particularly non-small cell lung cancer (NSCLC), and the rising demand for targeted therapies. These inhibitors, such as erlotinib, gefitinib, and osimertinib, play a crucial role in blocking the activity of EGFR, a protein involved in the growth of cancer cells. They have shown promising results in improving survival rates for patients with EGFR-mutated cancers. Recent developments focus on next-generation inhibitors designed to overcome resistance and improve efficacy. Ongoing clinical trials are expanding their use, including in combination therapies. As personalized medicine advances, the demand for these therapies is expected to rise. Additionally, improvements in diagnostics and biomarkers are enhancing patient selection, driving the growth of the market.
